Back to search results

Safety of Gamma Glutamylcysteine (GGC) for Mild Cognitive Impairment (MCI)

This study is looking at the safety of an oral supplement called Gamma Glutamylcysteine (GGC) for people with Mild Cognitive Impairment (MCI). Researchers want to see if different doses (400mg, 800mg, or 1200mg per day) are safe when taken for three months. They will check for any abnormal kidney or liver function tests and any side effects. This information will help them plan larger studies in the future. You might be able to join if you are 55-80 years old, have memory complaints, an MCI diagnosis, and can read and write in English. The current recruitment status is unclear.

Study design
This is an open-label, single-center study with a planned enrollment of 9 participants. It is designed to test increasing doses of Gamma Glutamylcysteine (GGC).
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will assess side effects and kidney/liver function for up to 3 months after starting the supplement.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07583251

Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

Recruiting
PHASE1Ages 55–80InterventionalPrevention
Pravat Mandal
~9 participants
Updated 2026-08-07 on ClinicalTrials.gov
What's tested:Gamma- GlutamylcysteineGamma- Glutamylcusteine

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
No. of participants with abnormal kidney and liver function tests after 30 days of supplementation.
Measured over 1 month
+4 more outcomes measured

Conditions

Mild Cognitive Impairment (MCI)

Explore related trials

Mild cognitive disorder

NCT07583251

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UPMC Presbyterian Hospital

    Pittsburgh, Pennsylvaniastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Pravat Mandal, PhD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

Pravat Pravat K MANDAL
[email protected]
4126999561
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • No. of participants with abnormal kidney and liver function tests after 30 days of supplementation.1 month

    Safety: Creatinine not more than 1.5mg/dL, AST and ALT levels not more than 1.5 X ULN.

  • Number of participants with treatment-related adverse events with one dose of GGC as assessed by CTCAE.3 months

    Safety and Tolerability

  • Number of participants with treatment-related adverse events with two doses of GGC as assessed by CTCAE.3 months

    Safety and tolerability

  • Number of participants with treatment-related adverse events with three doses of GGC as assessed by CTCAE.3 months

    Safety and tolerabitily

  • Number of participants with abnormal laboratory test results after 3 months of GGC supplementation.3 months

    Safety and tolerability: The number of participants experiencing clinically significant abnormal laboratory test results (hematology, kidney, and liver function tests) during 3 months of GGC supplementation, compared with baseline.